Literature DB >> 11213739

Management of posteriorly dislocated intraocular lens using pars plana vitrectomy.

M S Seo1, C R Kim, H J Nah, Y Lee, Y G Park.   

Abstract

In order to evaluate the results of pars plana vitrectomy (PPV) for the treatment of posteriorly dislocated intraocular lens (PC-IOL), we retrospectively examined and analyzed the hospital records of patients who had undergone PPV to exchange or reposition a PC-IOL dislocated into the vitreous cavity. Of 20 eyes in 20 patients, IOL exchange was performed in 6 eyes, and IOL repositioning in 14 eyes. Posteriorly dislocated IOL occurred in 14 eyes during or within 2 days, and in 6 eyes 6 months after the IOL implantation. Thirteen eyes were surgically treated early after the occurrence, within 3 days, while 7 eyes were treated later, between 5 to 7 days. Compared with preoperative best-corrected visual acuity, the final visual acuity improved more than 2 lines in 12 eyes. With no significant difference on the statistics, earlier visual rehabilitation seemed to be shown in late-treated patients than in early-treated. Accordingly, a posterior dislocation of IOL can be successfully treated with PPV, and barring any serious complications such as retinal detachment, there is no need for surgery immediately following the occurrence.

Entities:  

Mesh:

Year:  2000        PMID: 11213739     DOI: 10.3341/kjo.2000.14.2.80

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  2 in total

1.  Intraocular lens dislocation: a novel in-situ scleral refixation technique using a 25 Gauge trocar in the anterior chamber.

Authors:  Fabrizio Giansanti; Ruggero Tartaro; Tomaso Caporossi; Vittoria Murro; Alfonso Savastano; Francesco Barca; Daniela Bacherini; Tito Fiore; Carlo Cagini; Stanislao Rizzo
Journal:  BMJ Open Ophthalmol       Date:  2018-11-23

2.  A Comparison of Clinical Outcomes of Dislocated Intraocular Lens Fixation between In Situ Refixation and Conventional Exchange Technique Combined with Vitrectomy.

Authors:  Sun Jung Eum; Myung Jun Kim; Hong Kyun Kim
Journal:  J Ophthalmol       Date:  2016-03-29       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.